Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition.

STAT1 alternative polyadenylation eIF4A immune checkpoints intronic polyadenylation melanoma silvestrol translation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
24 Feb 2022
Historique:
received: 20 01 2022
revised: 20 02 2022
accepted: 21 02 2022
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 11 3 2022
Statut: epublish

Résumé

Targeting the translation initiation complex eIF4F, which binds the 5' cap of mRNAs, is a promising anti-cancer approach. Silvestrol, a small molecule inhibitor of eIF4A, the RNA helicase component of eIF4F, inhibits the translation of the mRNA encoding the signal transducer and activator of transcription 1 (STAT1) transcription factor, which, in turn, reduces the transcription of the gene encoding one of the major immune checkpoint proteins, i.e., programmed death ligand-1 (PD-L1) in melanoma cells. A large proportion of human genes produce multiple mRNAs differing in their 3'-ends through the use of alternative polyadenylation (APA) sites, which, when located in alternative last exons, can generate protein isoforms, as in the

Identifiants

pubmed: 35267483
pii: cancers14051177
doi: 10.3390/cancers14051177
pmc: PMC8909304
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Genome Biol. 2019 Dec 30;20(1):300
pubmed: 31888698
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Prod Rep. 2021 Jan 1;38(1):18-23
pubmed: 32699874
PLoS One. 2013 Sep 26;8(9):e76136
pubmed: 24086701
Oncogene. 2018 Aug;37(34):4639-4661
pubmed: 29765155
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nature. 2014 Sep 4;513(7516):65-70
pubmed: 25079319
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4660-5
pubmed: 10781071
J Clin Invest. 2008 Jul;118(7):2651-60
pubmed: 18551192
Nat Cancer. 2021 Dec;2(12):1251-1253
pubmed: 35121906
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Cell Cycle. 2016 Sep 16;15(18):2405-9
pubmed: 27533468
Nature. 2014 Sep 4;513(7516):105-9
pubmed: 25079330
Sci Rep. 2019 Mar 13;9(1):4302
pubmed: 30867517
Mol Cell. 2017 Nov 16;68(4):808-820.e5
pubmed: 29129640
Nat Commun. 2019 Dec 16;10(1):5713
pubmed: 31844050
PLoS One. 2009;4(4):e5223
pubmed: 19401772
Elife. 2021 Jul 02;10:
pubmed: 34213415
Nucleic Acids Res. 2020 Jan 8;48(D1):D174-D179
pubmed: 31617559
BMB Rep. 2019 Apr;52(4):289-294
pubmed: 30940323
Front Immunol. 2021 Jul 01;12:614773
pubmed: 34276642
Genome Biol. 2014;15(10):476
pubmed: 25273840
PLoS One. 2013;8(3):e49721
pubmed: 23472063
Mol Cell. 2011 Sep 16;43(6):927-39
pubmed: 21925381
Biomolecules. 2021 Oct 15;11(10):
pubmed: 34680158
RNA Biol. 2017 Jul 3;14(7):865-890
pubmed: 28453393
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Vaccines (Basel). 2020 Dec 04;8(4):
pubmed: 33291616
Front Immunol. 2020 Sep 08;11:2151
pubmed: 33013906
Mol Immunol. 2021 Jan;129:56-62
pubmed: 32948333
Front Immunol. 2017 Jun 30;8:765
pubmed: 28713384
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32601081
Front Mol Biosci. 2021 Mar 23;8:622643
pubmed: 33834038
ACS Chem Biol. 2013 Jul 19;8(7):1519-27
pubmed: 23614532
Ann Surg Oncol. 2021 Aug;28(8):4098-4099
pubmed: 33987757
Front Endocrinol (Lausanne). 2013 May 08;4:53
pubmed: 23658553
Genome Res. 2013 Dec;23(12):2078-90
pubmed: 24072873
Anat Rec. 1999 Jun 1;255(2):116-29
pubmed: 10359513
Nat Rev Genet. 2008 Feb;9(2):102-14
pubmed: 18197166
Nat Commun. 2014 Nov 21;5:5465
pubmed: 25413384
Eur J Immunol. 2016 Jun;46(6):1490-503
pubmed: 27005442
Gene. 2014 Oct 15;550(1):93-100
pubmed: 25123787
Immunity. 2008 Jan;28(1):64-74
pubmed: 18191595
Genome Res. 2018 Oct;28(10):1427-1441
pubmed: 30143597
Mol Cell. 2018 Apr 5;70(1):175-187.e8
pubmed: 29576526
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9785-90
pubmed: 19497879
Cell Rep. 2016 Jun 14;15(11):2340-7
pubmed: 27239032
Cell. 2018 Nov 29;175(6):1492-1506.e19
pubmed: 30449617
Nat Med. 2018 Dec;24(12):1877-1886
pubmed: 30374200
Am J Anat. 1987 Jan;178(1):1-10
pubmed: 3825959
Wiley Interdiscip Rev RNA. 2012 May-Jun;3(3):385-96
pubmed: 22012871
Immunology. 2021 Sep;164(1):190-206
pubmed: 33987830
Cancer Immunol Res. 2015 Jun;3(6):689-701
pubmed: 25614511
Nat Rev Cancer. 2021 Sep;21(9):558-577
pubmed: 34341537
Genome Res. 2012 Jun;22(6):1173-83
pubmed: 22454233
Elife. 2021 Jul 02;10:
pubmed: 34213414
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell Rep. 2019 Jan 2;26(1):94-107.e7
pubmed: 30605689
Nat Rev Cancer. 2016 Feb;16(2):121-6
pubmed: 26822578
Anat Sci Int. 2020 Jun;95(3):323-333
pubmed: 32067190
Nat Commun. 2018 Apr 30;9(1):1716
pubmed: 29712909
Science. 2008 Jun 20;320(5883):1643-7
pubmed: 18566288

Auteurs

Biswendu Biswas (B)

Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France.
Biologie de l'ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France.
Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France.
INSERM U981, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France.

Ramdane Guemiri (R)

INSERM U981, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France.

Mandy Cadix (M)

Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France.
Biologie de l'ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France.
Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France.

Céline M Labbé (CM)

Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France.
Biologie de l'ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France.
Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France.

Alina Chakraborty (A)

Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France.
Biologie de l'ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France.
Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France.

Martin Dutertre (M)

Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France.
Biologie de l'ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France.
Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France.

Caroline Robert (C)

INSERM U981, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France.

Stéphan Vagner (S)

Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France.
Biologie de l'ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France.
Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France.

Classifications MeSH